{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:22:58Z","timestamp":1787235778167,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ophtha.2014.06.050","type":"journal-article","created":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T12:19:13Z","timestamp":1410005953000},"page":"2380-2386","source":"Crossref","is-referenced-by-count":88,"title":["Long-Term Effects of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct01603355","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01717170","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marina","family":"Mesquida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Molins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-1564","authenticated-orcid":false,"given":"Victor","family":"Lloren\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8685-766X","authenticated-orcid":false,"given":"Maite","family":"Sainz de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.06.050_bib1","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of macular edema on visual acuity in uveitis","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.06.050_bib2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/bjophthalmol-2012-303052","article-title":"Systematic correlation of morphologic alterations and retinal function in eyes with uveitis-associated cystoid macular oedema during development, resolution and relapse","volume":"97","author":"Munk","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib3","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","article-title":"Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema","volume":"121","author":"Levin","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.06.050_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/09273948.2010.509530","article-title":"Clinical review: update on treatment of inflammatory macular edema","volume":"19","author":"Ossewaarde-van Norel","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2014.06.050_bib5","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2013.08.001","article-title":"Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums","volume":"43","author":"Navarro","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2014.06.050_bib7","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s00417-012-2243-x","article-title":"Tocilizumab treatment for recalcitrant uveitic macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib8","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema","volume":"251","author":"Ad\u00e1n","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.06.050_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine\u201440 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2014.06.050_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/bj2650621","article-title":"Interleukin-6 and the acute phase response","volume":"265","author":"Heinrich","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.ophtha.2014.06.050_bib14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.7150\/ijbs.4666","article-title":"Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases","volume":"8","author":"Tanaka","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ophtha.2014.06.050_bib15","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/art.24126","article-title":"Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses","volume":"58","author":"Fujimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2014.06.050_bib16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2567.2006.02433.x","article-title":"Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus","volume":"119","author":"Liang","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.ophtha.2014.06.050_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI114749","article-title":"Dysregulated interleukin 6 expression produces a syndrome resembling Castleman\u2019s disease in mice","volume":"86","author":"Brandt","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2014.06.050_bib19","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1073\/pnas.0802218105","article-title":"IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis","volume":"105","author":"Serada","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2014.06.050_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.exer.2010.04.009","article-title":"Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses","volume":"91","author":"Hohki","year":"2010","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2014.06.050_bib21","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1167\/iovs.10-6272","article-title":"Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis","volume":"52","author":"Haruta","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.06.050_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/092739490500282","article-title":"Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts Eye & Ear experience and review of previous studies","volume":"12","author":"Perez","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2014.06.050_bib23","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1167\/iovs.05-0444","article-title":"Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis","volume":"46","author":"Curnow","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.06.050_bib24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4049\/jimmunol.136.3.928","article-title":"T\u00a0cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat","volume":"136","author":"Caspi","year":"1986","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ophtha.2014.06.050_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2014.06.050_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","article-title":"Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis","volume":"48","author":"Yoshimura","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2014.06.050_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/07853890.2013.771986","article-title":"Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases","volume":"45","author":"Alten","year":"2013","journal-title":"Ann Med"},{"key":"10.1016\/j.ophtha.2014.06.050_bib29","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2217\/imt.13.47","article-title":"Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?","volume":"5","author":"Tanaka","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ophtha.2014.06.050_bib30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2014.06.050_bib31","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2014.06.050_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab\u2014a novel therapy for non-organ-specific\u00a0autoimmune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2014.06.050_bib34","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis [letter]?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A\u00a0case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib36","first-page":"968180","article-title":"Refractory uveitis in patient with Castleman disease successfully treated with tocilizumab","volume":"2012","author":"Oshitari","year":"2012","journal-title":"Case Rep Ophthalmol Med [serial online]"},{"key":"10.1016\/j.ophtha.2014.06.050_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/s10165-012-0691-0","article-title":"Successful treatment with tocilizumab in a case of Cogan\u2019s syndrome complicated with aortitis","volume":"23","author":"Shibuya","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ophtha.2014.06.050_bib38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2014.06.050_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cei.12295","article-title":"Interleukin-6 blockade in ocular inflammatory diseases","volume":"176","author":"Mesquida","year":"2014","journal-title":"Clin Exp Immunol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014005843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014005843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T08:19:15Z","timestamp":1689495555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014005843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0161642014005843"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.06.050","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}